148
Participants
Start Date
January 31, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Sulfatinib
(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
Etoposide
(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
Isophosphamide
(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
Peking University People's Hospital, Beijing
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Department of Orthopaedic Surgery, Sixth People's Hospital, Shanghai Jiao Tong University,, Shanghai
Qilu Hospital of Shandong University, Jinan
Department of Orthopedic Surgery Chonnam National University, Donggu
Chonnam National University
OTHER
Peking University People's Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Ruijin Hospital
OTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER